Indian Bank (BOM:532814)

Inozyme Pharma Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	-	112,615	84,194	55,723	41,418	31,492
Depreciation & Amortization	-	5,429	5,311	5,324	6,009	6,369
Gain (Loss) on Sale of Assets	-	-17	19.1	-1.6	-30.5	4.2
Gain (Loss) on Sale of Investments	-	-2,481	-3,778	4,922	4,538	4,277
Provision for Credit Losses	-	42,975	55,894	88,109	94,082	77,878
Change in Other Net Operating Assets	-	-521,022	-925,864	-723,765	-414,049	-451,117
Other Operating Activities	-	45,012	29,752	15,226	125.8	8,150
Operating Cash Flow	-	-317,489	-754,471	-554,463	-267,908	-322,948
Capital Expenditures	-	-5,399	-6,266	-3,344	-3,231	-5,604
Sale of Property, Plant and Equipment	-	1,915	88.8	203.8	184	155.6
Investing Cash Flow	-	-3,484	-6,177	-3,140	-3,047	-5,449
Long-Term Debt Issued	-	-	-	-	-	40,000
Long-Term Debt Repaid	-	-20,000	-10,000	-	-6,000	-15,000
Net Debt Issued (Repaid)	-	-20,000	-10,000	-	-6,000	25,000
Issuance of Common Stock	-	-	40,000	-	16,500	-
Common Dividends Paid	-	-22,635	-18,050	-15,434	-10,316	-6,319
Total Dividends Paid	-	-22,635	-18,050	-15,434	-10,316	-6,319
Net Increase (Decrease) in Deposit Accounts	-	491,453	668,298	275,524	555,411	495,257
Other Financing Activities	-	-	-	-	-	-25.1
Financing Cash Flow	-	448,817	680,249	260,089	555,595	513,913
Net Cash Flow	-	127,845	-80,399	-297,514	284,641	403,295
Free Cash Flow	-	-322,888	-760,737	-557,807	-271,138	-328,552
Free Cash Flow Margin	-	-104.20%	-292.93%	-298.48%	-185.62%	-239.72%
Free Cash Flow Per Share	-	-239.72	-596.60	-447.88	-222.53	-290.92
Cash Income Tax Paid	-	260.2	8,895	136	121.8	197.2

Source: S&P Global Market Intelligence. Banks template. Financial Sources.